Browsing Tag
Kartos Therapeutics
1 post
Ipsen closes Kartos Therapeutics acquisition as $1.75bn potential bet moves into Phase III execution
Ipsen completes its Kartos Therapeutics acquisition, adding Phase III navtemadlin under a deal worth up to $1.75bn. See what comes next.